Samsung Biologics and Pfizer announce strategic collaboration for long-term manufacturing of biosimilars portfolio
INCHEON, S. KOREA, and NEW YORK, USA, June 8 2023 –Samsung Biologics (KRX:207940.KS) and Pfizer (NYSE: PFE) today announced a strategic partnership for the long-term commercial manufacturing of Pfizer’s multi-product portfolio. Samsung Biologics and Pfizer entered into an initial manufacturing agreement in March 2023 for a Pfizer product.
Under the terms of the new agreement, Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio covering oncology, inflammation, and immunology. Samsung will use its newest facility, Plant 4, for the manufacturing.
“We are pleased to extend the strategic collaboration with Pfizer as we share and support their strong vision to bring innovative solutions for patients around the globe,” said John Rim, President and CEO of Samsung Biologics. “This new meaningful partnership comes just as our Plant 4 is fully completed early this month as we had previously committed and are on the move for future expansion into our second campus in order to provide our clients with even more flexible and advanced manufacturing technology.”
“Pfizer is excited to continue our strategic partnership with Samsung Biologics Ltd. that aims to enable greater access to medicines for more patients across the world,” said Mike McDermott, Chief Global Supply Officer, Executive Vice President, Pfizer. “This commitment is a reflection of Pfizer’s trust in the Korean Pharmaceutical industry to address emerging health challenges.”
“Our collaboration with Samsung Biologics will have the potential to significantly improve the lives of patients globally,” added Dong-Wook Oh, Pfizer Korea Country Manager.
About Samsung Biologics Co., Ltd.
Samsung Biologics (KRX: 207940.KS) is a fully integrated, end-to-end CDMO service provider offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish as well as laboratory testing services at every stage for biopharmaceutical products. Our facilities are all cGMP compliant with bioreactors ranging from small to large scales to serve varying client needs. To maximize our operational efficiency and expand our capabilities in response to growing biomanufacturing demands, Samsung Biologics launched Plant 4, which will further advance the company’s standing as the world’s largest manufacturing facility at a single site—holding a 604KL total capacity—and announced plans to construct Plant 5, which will be operational in 2025. Additionally, Samsung Biologics America enables the company to work in closer proximity to clients based in the U.S. and Europe. We continue to upgrade our capabilities to accommodate our clients by investing in technologies such as an antibody-drug conjugate (ADC) facility, a dedicated mRNA manufacturing facility, and additional aseptic filling capacity. As a sustainable CDMO partner of choice, we are committed to on-time, in-full delivery of the products we manufacture with our flexible manufacturing solutions, operational excellence, and proven expertise.
Samsung Biologics Contact
Claire Kim, Head of Marketing and Global Communications